+91%

est. 2Y upside i

HealthcareSeries C

Medical device that provides a more effective, less invasive…

Rank

#783

Sector

Medical Devices

Est. Liquidity

~4Y

Data Quality

Data: Medium

Zenflow presents a compelling, albeit risky, equity opportunity.

Last updated: March 10, 2026

Bull (40%)+200%

Zenflow rapidly gains market share due to its first-line, office-based, reversible Spring System, reaching $70-80M in revenue by 2028. This strong commercial traction and differentiation justify a 9-10x revenue multiple, leading to a $720M valuation.

Base (35%)+75%

Zenflow achieves steady adoption in the competitive BPH market, growing revenue to $40-50M by 2028. The company maintains its niche with the office-based procedure, leading to a $420M valuation.

Bear (25%)-60%

Adoption is slower than expected due to strong incumbent competition and reimbursement challenges, with revenue stalling at $20-25M. This leads to a down round or acquisition at a significantly reduced valuation of $96M, wiping out most common stock value due to $80M in liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

33%

Investors hold $80M in liquidation preferences ahead of common stock, representing 33.3% of the current valuation.

Dilution Risk

high

Given high capital intensity and the need for significant commercialization investment, future funding rounds are likely, leading to further dilution.

Secondary Liquidity

limited

Platforms like Nasdaq Private Market and EquityZen offer some avenues for accredited investors to buy/sell shares, but it is not an active public market.

Questions to Ask at the Interview

Strategic questions based on Zenflow's data — designed to show you've done your homework.

  • 1

    “With FDA approval secured, what are the key strategies and milestones for accelerating commercial adoption of the Spring System, particularly in light of established competitors like UroLift and iTind from Boston Scientific and Olympus?”

  • 2

    “Given the high capital intensity of the medical device sector and the current $80M in liquidation preferences, how does Zenflow plan to manage future funding needs to minimize dilution for common shareholders while achieving a successful liquidity event?”

  • 3

    “The Spring System offers a unique office-based, reversible, and sexual function-preserving approach. How will Zenflow differentiate its value proposition to urologists and patients to drive market share in a BPH treatment market that already has ~60% penetration by various vendors?”

Community

Valuation Sentiment

Our model estimates +91% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.